Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (198)	12/25/2002 8:38:19 PM
From: John McCarthy	Read Replies (1) \| Respond to of 447

fwiw - Probably got this wrong but sometimes referred to as OSI-774 -or- Tarceva -or- Erlotinib (?) A search brings back 30 records - some may be duplicates - but I have not checked. All trials are still recruiting or have NOT started ... A few examples - P2 Drug: rhuMAb VEGF (Avastin) and OSI-774 (Tarceva) Lung Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Squamous Cell clinicaltrials.gov Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed clinicaltrials.gov P3 clinicaltrials.gov clinicaltrials.gov clinicaltrials.gov Source: clinicaltrials.gov John McCarthy